Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million
Verastem and Infinity Pharmaceuticals have entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib.
